Next 10 |
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as ...
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time t...
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing o...
MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announced today that i...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm ® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (...
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has receive...
2024-03-21 17:45:20 ET IntelGenx Technologies Corp. (IGXT) Q4 2023 Results Conference Call March 21, 2024 08:30 AM ET Company Participants Stephen Kilmer - Investor Relations Dwight Gorham - Chief Executive Officer André Godin - President and Chief Financial...
2024-03-21 07:49:22 ET More on IntelGenx Seeking Alpha’s Quant Rating on IntelGenx Financial information for IntelGenx Read the full article on Seeking Alpha For further details see: IntelGenx GAAP EPS of -$0.01, revenue of $0.43M
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency...
News, Short Squeeze, Breakout and More Instantly...
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as ...
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time t...
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing o...